Our Team

Brian Mehling, M.D., M.S. is the Founder and Principal of Mehling Family Office, a private investment platform dedicated primarily to advancing innovation in medicine, biotechnology, and life sciences. The Family Office focuses on strategic capital deployment into high-impact healthcare sectors including regenerative medicine, stem cell science, translational research, advanced therapeutics, longevity science, and medical technology.

Drawing on his decades of experience as a practicing orthopedic trauma surgeon and medical researcher, Dr. Mehling applies a clinically informed perspective to investment strategy. Mehling Family Office prioritizes opportunities where rigorous science, regulatory discipline, and ethical clinical implementation intersect with scalable innovation. The Office partners with researchers, physicians, and biotech entrepreneurs to accelerate the development of breakthrough therapies aimed at improving patient outcomes and expanding access to advanced medical care.

A core pillar of the Family Office is responsible advancement of regenerative and cellular medicine. Leveraging Dr. Mehling’s leadership in stem cell research and clinical application, the platform supports ventures operating within full regulatory frameworks and internationally recognized scientific standards. Investments are evaluated not only on financial merit, but on clinical validity, safety, and long-term therapeutic potential.

Mehling Family Office maintains a long-term, multi-generational investment horizon, emphasizing disciplined capital stewardship, scientific integrity, and meaningful medical impact. Under Dr. Mehling’s leadership, the Office serves as both a strategic capital partner and a catalyst for transformative progress in healthcare innovation.

Katarina Novakova, MSc, is an international healthcare and longevity investor and Managing Director at the Mehling Family Office, where she collaborates on strategic initiatives across biotechnology, regenerative medicine, and healthspan innovation. Bringing more than two decades of global experience, she operates at the intersection of science, capital, and cross-border partnership development, working alongside physicians, researchers, and institutional and private investors throughout the United States, Europe, and international markets to advance next-generation therapeutic platforms and scalable longevity solutions.

Multilingual and having lived on several continents, Katarina offers a distinctly global perspective on capital deployment, strategic collaboration, and long-term value creation in precision medicine and human health. Her work focuses on identifying high-impact opportunities, structuring partnerships, and aligning visionary science with patient-centered outcomes and sustainable investment performance.

She has been a member of the World Economic Forum’s New Champions community since 2022 and is actively engaged with global leadership and investor networks, including Nexus, where she collaborates with family offices, philanthropists, and industry leaders shaping the future of healthcare, biotechnology, and human performance. Katarina holds a master’s degree in Economics and Business Management and is recognized for building trusted international relationships that translate innovation into measurable clinical and financial impact.